Molecular Biosystems (US) MBI starts Phase II trials for Oralex:
This article was originally published in Clinica
Molecular Biosystems (US) has started Phase II clinical trials for Oralex, its gastrointestinal agent for enhancing abdominal imaging (see Clinica No 657, p 18).
You may also be interested in...
Advanced Medical Solutions said it will buy Raleigh Adhesive Coatings for £22m ($29m) in cash to strengthen its overall wound care business.
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.
Lilly has launched a similar antibody product, but demand is expected to outpace supply for the foreseeable future.